VIREO GROWTH INC.

VREOF ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Operating Activities
Net Income $-68.1M $-28.0M $-25.5M $-42.5M $-33.7M $-22.9M
Depreciation & Amortization $16.1M $2.5M $2.9M $3.3M $3.0M $2.5M
Depreciation $11.3M $292.7K $469.9K $653.1K $624.6K $413.1K
Amortization $5.7M $720.1K $678.9K $676.6K $817.2K
Stock-Based Compensation $18.7M $3.6M $4.2M $2.7M $5.2M $12.8M
Net Cash from Operating Activities $3.7M $-10.2M $-965.9K $-18.1M $-30.5M $-10.9M
Investing Activities
Capital Expenditures $28.3M $11.7M $5.0M $5.6M $18.0M $8.4M
Business Acquisitions
Net Cash from Investing Activities $8.8M $-8.1M $-3.5M $-5.6M $-7.2M $12.9M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $18.4M $94.0M $5.3M $23.7M $25.8M $15.9M
Net Change in Cash
Free Cash Flow $-24.6M $-21.9M $-5.9M $-23.6M $-48.6M $-19.4M